AXL inhibition improves BRAF-targeted treatment in melanoma

More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to a more aggressive mesenchymal phenotype, attributed with AXL(high) molecular profile in melanoma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyakas, Marta, Fleten, Karianne Giller, Haugen, Mads Haugland, Engedal, Nikolai, Sveen, Christina, Farstad, Inger Nina, Flørenes, Vivi Ann, Prasmickaite, Lina, Mælandsmo, Gunhild Mari, Seip, Kotryna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948193/
https://www.ncbi.nlm.nih.gov/pubmed/35332208
http://dx.doi.org/10.1038/s41598-022-09078-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948193/
https://www.ncbi.nlm.nih.gov/pubmed/35332208
http://dx.doi.org/10.1038/s41598-022-09078-z

Ejemplares similares